Neumora Therapeutics (NMRA) Non Operating Income (2022 - 2026)

Neumora Therapeutics' Non Operating Income history runs 5 years deep, the most recent figure standing at -$564000.0 for Q1 2026.

• On a quarterly basis, Non Operating Income fell 118.5% year-over-year to -$564000.0 in Q1 2026; TTM through Mar 2026 was $745000.0, a 95.5% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 78.05% from the prior year.
• Non Operating Income climbed to -$564000.0 in Q1 2026 per NMRA's latest filing, from -$970000.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $6.4 million in Q1 2024 and bottomed at -$970000.0 in Q4 2025.
• The 5-year median for Non Operating Income is $3.6 million (2023), against an average of $2.9 million.
• Across the five-year window, Non Operating Income jumped 205.01% in 2023 and tumbled 123.64% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $2.2 million in 2022, then soared by 155.75% to $5.5 million in 2023, then dropped by 25.97% to $4.1 million in 2024, then tumbled by 123.64% to -$970000.0 in 2025, then soared by 41.86% to -$564000.0 in 2026.
• Per Business Quant, the three latest NMRA Non Operating Income figures stand at -$564000.0 (Q1 2026), -$970000.0 (Q4 2025), and $945000.0 (Q3 2025).